1. Home
  2. JZXN vs BIVI Comparison

JZXN vs BIVI Comparison

Compare JZXN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JZXN

Jiuzi Holdings Inc.

HOLD

Current Price

$0.86

Market Cap

2.0M

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.35

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JZXN
BIVI
Founded
2019
2013
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
8.5M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
JZXN
BIVI
Price
$0.86
$1.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.3M
107.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.62
52 Week High
$8.50
$9.09

Technical Indicators

Market Signals
Indicator
JZXN
BIVI
Relative Strength Index (RSI) 39.14 58.73
Support Level $0.21 $1.05
Resistance Level $1.19 $1.68
Average True Range (ATR) 0.36 0.11
MACD -0.07 0.02
Stochastic Oscillator 5.42 78.95

Price Performance

Historical Comparison
JZXN
BIVI

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: